靶向腋窝淋巴结切除在新辅助化疗后腋窝淋巴结评估中的应用

doi:10.3969/j.issn.2095-9400.2021.06.008

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1458 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的：探讨靶向腋窝淋巴结切除术（TAD）在评估乳腺癌患者新辅助化疗后腋窝淋巴结转移情况中的应用。方法：前瞻性纳入2015年6月至2020年5月期间丽水市中心医院乳腺疾病诊疗中心收治的行新辅助化疗患者57例，其中31例行新辅助化疗前先在超声引导下将金属标记夹植入经细针穿刺证实转移的腋窝淋巴结，完成化疗后行手术时先在超声引导下对标记淋巴结行穿刺染色定位后行标记的腋窝淋巴结切除，同时行前哨淋巴结活检后再行腋窝淋巴结清扫术（TAD组）。另26例行新辅助化疗后，术中单纯行前哨淋巴结活检后再行腋窝淋巴结清扫术（对照组），比较两组前哨淋巴结检出率、准确率、灵敏度及假阴性率。结果：57例患者中至少检出1枚前哨淋巴结者有53例，前哨淋巴结检出率为92.98%，其中TAD组31例，对照组26例。TAD组淋巴结检出率为100%（31/31），灵敏度为94.44%（17/18），假阴性率为5.56%（1/18），准确率为96.77%（30/31）。对照组淋巴结检出率为84.62%（22/26），灵敏度为62.50%（10/16），假阴性率为37.50%（6/16），准确率为72.73%（16/22）。TAD组的淋巴结检出率、灵敏度及准确率明显高于对照组（P＜0.05）；TAD组假阴性率明显低于对照组（P＜0.05）。结论：腋窝淋巴结阳性的乳腺癌患者新辅助化疗后行TAD联合前哨淋巴结活检相较于单纯行前哨淋巴结活检更能真实反映腋窝淋巴结转移情况。

	服务
	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	刘鹏鹏
	周毅
	蔡仕彬
	虞凯杰
	冯娅琴
	吴爱芬
	陈述政

关键词 ：乳腺癌, 标记夹, 靶向腋窝淋巴结切除, 前哨淋巴结活检, 新辅助化疗

Abstract：Objective: To explore the application of targeted axillary lymph node resection in the assessment of residual axillary lymph node metastasis in breast cancer patients after neoadjuvant chemotherapy. Methods: Totally 57 patients who were admitted to the Breast Disease Diagnosis and Treatment Center of Lishui Central Hospital and underwent neoadjuvant chemotherapy from June 2015 to May 2020 were prospectively errolled in this study. In 31 patients undergoing neoadjuvant chemotherapy, the marker clip was implanted into the metastatic axillary lymph node, confirmed by fine needle aspiration under ultrasound guidance. After chemotherapy, the labeled lymph node was punctured and stained under ultrasound guidance and then sentinel lymph node biopsy was performed at the same time as the marker removal of axillary lymph nodes (TAD), and then axillary lymph node was dissected (for TAD group). The remaining 26 cases received neoadjuvant chemotherapy alone. After the
chemotherapy was completed, sentinel lymph node biopsy was performed and then axillary lymph node was dissected (for the control group). Statistical analysis was made of the lymph node detection rate, accuracy, sensitivity and false negative rate of targeted axillary lymph node resection and sentinel lymph node biopsy. Results: Among 57 patients, at least one sentinel lymph node was detected in 53 cases. The detection rate of SLN was 92.98%. Among them, 31 cases were in the TAD group and 26 cases were in the control group. The detection rate of lymph nodes in the TAD group was 100.00% (31/31), with the average number of lymph nodes being 3.39 per case, the sensitivity 94.44% (17/18), the false negative rate 5.56% (1/18), and the accuracy rate 96.77%(30/31). The detection rate of lymph nodes in the control group was 84.62% (22/26), with the average number of lymph nodes detected being 3.38 per case, the sensitivity 62.50% (10/16), the false negative rate 37.50% (6/16), and the accuracy rate 72.73% (16/22). The detection rate, sensitivity and accuracy of lymph nodes in the TAD group were significantly higher than those of the control group, which showed statistical differences (P<0.05), and the false negative rate of the TAD group was significantly lower than that of the control group, with statistical differences (P<0.05). Conclusion: Targeted axillary lymph node dissection for breast cancer patients after neoadjuvant chemotherapy can actually reflect the axillary lymph node metastasis, compared with sentinel lymph node biopsy alone.

Key words： breast cancer marker clip targeted axillary lymph node dissection sentinel lymph node biopsy neoadjuvant chemotherapy

收稿日期: 2021-01-31

基金资助:丽水市科技计划项目（2017ZDXK10）。

通讯作者: 陈述政，主任医师，Email：dr.susan@163.com。 E-mail: dr.susan@163.com

作者简介: 刘鹏鹏，住院医师，Email：puwailiu2015@163.com。

链接本文:

https://xb.wmu.edu.cn/CN/10.3969/j.issn.2095-9400.2021.06.008 或 https://xb.wmu.edu.cn/CN/Y2021/V51/I6/473

参考文献：
[1] 中国抗癌协会乳腺癌专业委员会. 中国晚期乳腺癌临床诊疗专家共识(2018版)[J]. 中华肿瘤杂志, 2018, 40(9): 703-713.
[2] GRADISHAR W J, ANDERSON B O, ABRAHAM J, et al. Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2020, 18(4): 452-478.
[3] DIEGO E J, MCAULIFFE P F, SORAN A, et al. Axillary staging after neoadjuvant chemotherapy for breast cancer: A pilot study combining sentinel lymph node biopsy with radioactive seed localization of pre-treatment positive axillary lymph nodes[J]. Ann Surg Oncol, 2016, 23(5): 1549-1553.
[4] WEISS A, MITTENDORF E A, DESNYDER S M, et al. Expanding implementation of ACOSOG Z0011 in surgeon practice[J]. Clin Breast Cancer, 2018, 18(4): 276-281.
[5] GALIMBERTI V, COLE B F, VIALE G, et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial[J]. Lancet Oncol, 2018, 19(10): 1385-1393.
[6] NOGI H, UCHIDA K, MIMOTO R, et al. Long-term follow-up of node-negative breast cancer patients evaluated via sentinel node biopsy after neoadjuvant chemotherapy[J]. Clin Breast Cancer, 2017, 17(8): 644-649.
[7] MOCELLIN S, GOLDIN E, MARCHET A, et al. Sentinel node biopsy performance after neoadjuvant chemotherapy in locally advanced breast cancer: A systematic review and meta-analysis[J]. Int J Cancer, 2016, 138(2): 472-480.
[8] GREEN M, NEAMONITOU F, VIDYA R. Conservative management of positive axilla after neoadjuvant systemic therapy-the need for, and review of, techniques used for lymph node localization[J]. Clin Breast Cancer, 2018, 18(5): e739-e742.
[9] BOUGHEY J C, BALLMAN K V, LE-PETROSS H T, et al. Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0-T4, N1-N2) who receive neoadjuvant chemotherapy: Results from ACOSOG Z1071 (Alliance)[J]. Ann Surg, 2016, 263(4): 802-807.
[10] CAUDLE A S, YANG W T, KRISHNAMURTHY S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: Implementation of targeted axillary dissection[J]. J Clin Oncol, 2016, 34(10): 1072-1078.
[11] SIMONS J M, VAN NIJNATTEN T J A, VAN DER POL C C, et al. Diagnostic accuracy of different surgical procedures for axillary staging after neoadjuvant systemic therapy in node-positive breast cancer: A systematic review and meta-analysis[J]. Ann Surg, 2019, 269(3): 432-442.
[12] BOILEAU J F, POIRIER B, BASIK M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: The SN FNAC study[J]. J Clin Oncol, 2015, 33(3): 258-264.
[13] BOUGHEY J C, BALLMAN K V, HUNT K K, et al. Axillary ultrasound after neoadjuvant chemotherapy and its impact on sentinel lymph node surgery: Results from the American
College of Surgeons Oncology Group Z1071 Trial (Alliance) [J]. J Clin Oncol, 2015, 33(30): 3386-3393.
[14] BOUGHEY J C, SUMAN V J, MITTENDORF E A, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: The ACOSOG Z1071 (Alliance) clinical trial[J]. JAMA, 2013, 310(14): 1455-1461.
[15] CABIOGLU N, KARANLIK H, KANGAL D, et al. Improved false-negative rates with intraoperative identification of clipped nodes in patients undergoing sentinel lymph node biopsy after neoadjuvant chemotherapy[J]. Ann Surg Oncol, 2018, 25(10): 3030-3036.
[16] TRINH L, MIYAKE K K, DIRBAS F M, et al. CT-Guided wire localization for involved axillary lymph nodes after neo-adjuvant chemotherapy in patients with initially node-positive breast cancer[J]. Breast J, 2016, 22(4): 390-396.
[17] HARTMANN S, REIMER T, GERBER B, et al. Wire localization of clip-marked axillary lymph nodes in breast cancer patients treated with primary systemic therapy[J]. Eur J Surg Oncol, 2018, 44(9): 1307-1311.
[18] PLECHA D, BAI S, PATTERSON H, et al. Improving the accuracy of axillary lymph node surgery in breast cancer with ultrasound-guided wire localization of biopsy proven metastatic lymph nodes[J]. Ann Surg Oncol, 2015, 22(13): 4241-4246.